Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
ANN ARBOR, Mich., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced that president and chief executive officer, Tim M. Mayleben, will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 13, 2016 at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time.
A live, listen-only webcast of the presentation can be accessed on the investor relations section of the Esperion website at www.esperion.com. A webcast replay of the presentation will be available approximately one hour after completion and will be archived on the Company's website for 90 days following the event.
Esperion’s Commitment to Cardiometabolic Disease
Esperion is committed to improving the lives of patients with hypercholesterolemia by developing therapies to lower LDL-C. Esperion scientists discovered ETC-1002 and the LDL-C lowering therapy is in late stage development. Esperion plans to develop both ETC-1002 and a fixed dose combination of ETC-1002 and ezetimibe with a particular focus on patients with hypercholesterolemia who are considered intolerant of statin therapy. It is estimated that approximately 10% of patients who are prescribed statins, 3.5 million patients in the U.S., are considered statin intolerant.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia. ETC-1002 (bempedoic acid), the Company’s lead product candidate, is an inhibitor of ATP Citrate Lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway. ETC-1002 inhibits cholesterol synthesis, decreases intracellular cholesterol, up-regulates LDL-receptors, and causes increased LDL-C clearance and reduced plasma levels of LDL-C. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc.
Media Contact: Elliot Fox W2O Group 212.257.6724 [email protected] Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 [email protected]
